|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
The administration of low-dose lung irradiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response. The present study will evaluate the efficacy of treatment with low-dose pulmonary radiotherapy added to standard support therapy, in hospitalized patients with respiratory symptoms due to COVID-19 pneumonia, who do not experience improvement with conventional medical therapy and are not subsidiaries of ICU
Description: Clinical improvement of respiratory symptoms due to COVID-19 pneumonia after the treatment, measured as blood oxygen saturation levelsMeasure: blood oxygen saturation level Time: 48 hours
Description: radiological improvement of respiratory symptoms due to COVID-19 pneumonia after the treatment.Measure: Torax X-ray Time: 48 hours
Description: number of days of hospital stay.Measure: Hospitalization Time: 2 months
Description: Number of days free of assisted mechanical respiration.Measure: days free of assisted mechanical respiration Time: 3 month
Description: number of deathsMeasure: Mortality Time: 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports